Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

Immuno oncology Europe company poll

Interview 20 Apr 2017

Which EU Immuno-Oncology Company are you Cheering for?

Immuno-oncology represents a huge breakthrough towards the search for a cancer cure. Biotechs all around Europe are developing innovative ways of helping our own immune system fight tumors, which one do you think is doing it best? The field of immuno-oncology is overcrowded, and there’s plenty of companies pushing to make their cutting-edge technology a […]

April 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Cancer Amino Acids Diet Research

News and Trends 19 Apr 2017

Researchers Unmask How a New Diet can help Cure Cancer

Researchers from the University of Glasgow and the Cancer Research UK Beatson Institute found that cancer cells are dependent on specific amino acids. In a new study published today in Nature, researchers found that removing two non-essential amino acids – serine and glycine – from the diet of mice slowed the development of lymphoma and intestinal […]

April 19, 2017 - 3 minutesmins - By Melanie De Almeida

Galapagos US Public Offering

News and Trends 19 Apr 2017

Galapagos Shoots Past its IPO in a New Public Round of €315M

After its record €277 IPO on Nasdaq in 2015, Galapagos announced the pricing of its new US public offering at a massive €315M ($338M). Galapagos is clinging to its position as one of the biggest biotechs in Europe. While the Belgian biotech is currently pushing its rheumatoid arthritis candidate filgotinib through Phase III, the new US public offering could give […]

April 19, 2017 - 2 minutesmins - By Melanie De Almeida

shutterstock 597411959

News and Trends 19 Apr 2017

UPDATE: Novartis broadens CAR-T onslaught with FDA endorsement

UPDATE (19/04/2017): CTL019 has been granted Breakthrough Designation by the FDA for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Novartis and Kite have been in a tight race to bring the first CAR-T therapy to market: Novartis has staked out acute lymphoblastic leukemia (ALL) while Kite has gone for DLBCL. With this “tacit endorsement,” Novartis is encroaching on […]

April 19, 2017 - 3 minutesmins - By Evelyn Warner

Verona Pharma CF COPD IPO

News and Trends 19 Apr 2017

UPDATE: Verona sets terms & dials back its IPO goal to a still-hefty €75M

UPDATE: Verona set the terms for its US IPO yesterday and knocked $10M (€9.3M) off its target, now shooting for $75M (€70M). The public shares are expected to hit the NASDAQ exchange next week. Original Publication 04/04/2017 British Verona Pharma has filed for an IPO on Nasdaq to raise up to €81M ($86M). The funds should be […]

April 19, 2017 - 3 minutesmins - By Melanie De Almeida

Allergan Novartis NASH collaboration

News and Trends 18 Apr 2017

Two Big Pharma Players Team up to Take Over the NASH Space

Allergan has entered a clinical collaboration with Novartis to run a Phase IIb study combining its immunomodulator and Novartis’ FXR agonist for NASH. After Allergan snapped up Tobira’s cenicriviroc (CVC) last year in a €1.4B deal, the company is now taking the next step to advance its pipeline in the Non-Alcoholic SteatoHepatitis (NASH) race. The pharma company is going […]

April 18, 2017 - 3 minutesmins - By Melanie De Almeida

ADVERTISEMENT

Circassia Pharmaceuticals Allergy Halt

News and Trends 18 Apr 2017

Circassia Freezes its Allergy Portfolio after a Second Failed Clinical Trial

Circassia Pharmaceuticals will stop investing in its allergy programs due to two failed clinical trials in which the placebo beat its allergy immunotherapy. Circassia Pharmaceuticals has released the results from a Phase IIb trial for a house dust mite allergy immunotherapy. Although the treatment greatly reduced allergy symptoms in the patients, so did the placebo, making […]

April 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

biotech basel influential people

Best in Biotech 18 Apr 2017

The Top 12 Biotech Leaders You Should Know in Basel

After exploring Munich and the Golden Triangle, we head to another biotech hotspot full of people that should be on your list of who’s who. Basel is home to some really big biotech and pharma companies and it’s consequently a cornerstone of the excellence Switzerland has demonstrated in the industry (also seen in Zurich). As a key […]

April 18, 2017 - 6 minutesmins - By Denise Neves Gameiro

shutterstock 619620167

News and Trends 18 Apr 2017

Patent Eligibility: How to Tell if your Life Science Invention is Patentable

So you have an invention, but can you protect it with a patent? This primer will teach you about the criteria, from non-obviousness to inventiveness. How do we define “patent eligibility“? Broadly, the term means that an invention falls within a category of inventions for which the patent laws provide patent protection in general. Inventions […]

April 18, 2017 - 5 minutesmins - By External Contributor

Patrick Baeuerle Successful German Biotech Leader

Interview 17 Apr 2017

Meet One of the Most Successful German Biotech Leaders Ever

Patrick Baeuerle is the German biotech leader I wanted to interview the most (besides Simon Moroney from MorphoSys, who came to our Meetup in Munich last week). Patrick has explored and succeeded in just about every area of life sciences, be it as a highly cited academic researcher, a professor at Freiburg University, head of drug […]

April 17, 2017 - 6 minutesmins - By Philip Hemme

Ingmar Hoerr CureVac Labiotech

Inside Labiotech 14 Apr 2017

Why is Ingmar Hoerr, Co-Founder & CEO of CureVac, reading Labiotech.eu?

Leaders & Readers: I had a chat with Ingmar Hoerr about why he reads Labiotech.eu. He is the co-founder and CEO of CureVac, one of the most successful European biotechs. This interview has just been lightly edited for grammar. Why do you read Labiotech.eu, and how does it help you in your job? I really like the […]

April 14, 2017 - 2 minutesmins - By Editorial Team

PCI Biotech cancer norway

Startup Scout 14 Apr 2017

This Norwegian Biotech Aims to Unlock the Full Potential of Cancer Drugs

This week we visited the Norwegian PCI Biotech. Based in Oslo, this company has developed a light-sensitive technology, which allows to activate cancer drugs at specific sites of the body by targeted illumination. Mission: PCI Biotech focuses on the development of new therapies for the treatment of cancer based on its photochemical internalisation (PCI) technology. The PCI technology consists of a photosensitising […]

April 14, 2017 - 2 minutesmins - By Melanie De Almeida

ADVERTISEMENT